Dr. Stephanie Venn-Watson

He's like, this is the exact same presentation of fatty liver disease that you're seeing in dolphins that I'm seeing in my kids. And he's like, you're blowing my mind because dolphins don't eat sugar. They're not eating trans fats. It's not ultra-processed food.

Right? And it's just like, what? And so that started our 10-year journey in which we have worked together but independently. that jeff then did a study in which he looked at 237 kids and he did at the time they didn't have your wonderful test which everybody should get the test that mark just mentioned to assess your liver regardless of your who you are and your age everybody should get this test

Right? And it's just like, what? And so that started our 10-year journey in which we have worked together but independently. that jeff then did a study in which he looked at 237 kids and he did at the time they didn't have your wonderful test which everybody should get the test that mark just mentioned to assess your liver regardless of your who you are and your age everybody should get this test

Right? And it's just like, what? And so that started our 10-year journey in which we have worked together but independently. that jeff then did a study in which he looked at 237 kids and he did at the time they didn't have your wonderful test which everybody should get the test that mark just mentioned to assess your liver regardless of your who you are and your age everybody should get this test

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

Yeah, and for us, we keep going back to the dolphins. And for the dolphin, we call this the dolphin phenotype of fatty liver disease, the only change they had, they had moved to, they were eating a high fish, high fat fish called the eulachon. which is called a candlefish. It has so much fat in it that you can stick a wick in it. You can dry it, stick a wick in it, and be a candle.